Department of Nuclear Medicine, School of Medicine, Manisa Celal Bayar University, Uncubozkoy, 45030, Manisa, Turkey.
Department of Nuclear Medicine, Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkey.
Ann Nucl Med. 2022 Dec;36(12):1050-1058. doi: 10.1007/s12149-022-01794-w. Epub 2022 Oct 10.
This study aimed to investigate immunohistochemical staining of sodium iodide symporter (NIS) and its effect on response to I-131 therapy in differentiated thyroid carcinoma patients.
We evaluated NIS expression, the intracellular distribution of NIS, iodine-131 uptake in residual tissues on post-ablation I-131 whole body scan, and the ablation status after 100 mCi I-131 therapy. We also investigated NIS expression and localization in tumoral paraffin-embedded tissues.
In this retrospective study, 35 patients (mean age 44.17 ± 12.9 years, 27 female, 8 male) were studied. Twenty-one of these patients responded to radioiodine therapy, and 14 did not. NIS expression and iodine-131 uptake in residual tissues post-ablation I-131 whole body scan were not statistically significant. When we compared the patients who responded to radioiodine therapy and the poor responder group, NIS expression and iodine-131 uptake in residual tissues did not demonstrate statistically significant difference [(p = 0.308) (p = 0.985) respectively]. 47.6% of the patients in the successful ablation group and 85.7% in the unsuccessful ablation group had intracellular NIS immunostaining. The difference was not statistically significant (p = 0.139). 52.4% of the patients in the successful ablation group and 7% in the unsuccessful ablation group had NIS immunostaining at the basolateral membrane. The difference was statistically significant (p < 0.05).
In conclusion, we did not find any significant difference between successful and unsuccessful ablation groups in terms of NIS expression; however, we concluded that the intracellular (cytoplasmic) localization of NIS is one of the leading causes of ablation failure regardless of NIS expression in DTC patients.
本研究旨在探讨钠碘转运体（NIS）的免疫组织化学染色及其对分化型甲状腺癌患者接受碘-131 治疗反应的影响。
我们评估了 NIS 表达、NIS 的细胞内分布、残留组织在消融后碘-131 全身扫描中的摄取，以及 100mCi 碘-131 治疗后的消融状态。我们还研究了肿瘤石蜡包埋组织中 NIS 的表达和定位。
在这项回顾性研究中，共研究了 35 例患者（平均年龄 44.17±12.9 岁，27 例女性，8 例男性）。其中 21 例患者对放射性碘治疗有反应，14 例患者无反应。消融后碘-131 全身扫描中 NIS 表达和残留组织的碘-131 摄取无统计学意义。当我们比较对放射性碘治疗有反应和反应不良的患者组时，NIS 表达和残留组织的碘-131 摄取无统计学显著差异[（p=0.308）（p=0.985）分别]。成功消融组 47.6%的患者和不成功消融组 85.7%的患者有细胞内 NIS 免疫染色。差异无统计学意义（p=0.139）。成功消融组 52.4%的患者和不成功消融组 7%的患者在基底外侧膜有 NIS 免疫染色。差异有统计学意义（p<0.05）。
总之，我们没有发现成功消融组和不成功消融组之间在 NIS 表达方面有任何显著差异；然而，我们得出结论，无论 DTC 患者的 NIS 表达如何，NIS 的细胞内（细胞质）定位是消融失败的主要原因之一。
